There are roughly 7,700 new cases of endometrial cancer each year in the UK, of these around 170 women could be eligible for treatment with GSK's antibody, which has also been approved in the US ...
GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...